journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology

journal
https://www.readbyqxmd.com/read/28325583/optimizing-endometrial-cancer-follow-up-and-survivorship-care-for-rural-and-other-underserved-women-patient-and-provider-perspectives
#1
Teresa L Rutledge, Miria Kano, Dolores Guest, Andrew Sussman, Anita Y Kinney
OBJECTIVES: This study describes patient and provider attitudes on transitioning cancer surveillance visits and treatment of comorbid conditions to the primary care setting in a rural patient population as a strategy for minimizing financial and travel related barriers for patients while simultaneously enhancing quality and availability of health care options. METHODS: Focus group discussions and telephone interviews were conducted with endometrial cancer (EC) survivors and primary care providers (PCPs) to provide insights into post-treatment follow-up practices and the acceptability of transitioning follow-up to primary care setting utilizing a cancer survivorship care plan model...
March 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28318644/comparison-of-outcomes-for-mr-guided-versus-ct-guided-high-dose-rate-interstitial-brachytherapy-in-women-with-locally-advanced-carcinoma-of-the-cervix
#2
Sophia C Kamran, Matthias M Manuel, Linda P Cho, Antonio L Damato, Ehud J Schmidt, Clare Tempany, Robert A Cormack, Akila N Viswanathan
OBJECTIVE: The purpose was to compare local control (LC), overall survival (OS) and dose to the organs at risk (OAR) in women with locally advanced cervical cancer treated with MR-guided versus CT-guided interstitial brachytherapy (BT). METHODS: 56 patients (29 MR, 27 CT) were treated with high-dose-rate (HDR) interstitial BT between 2005-2015. The MR patients had been prospectively enrolled on a Phase II clinical trial. Data were analyzed using Kaplan-Meier (K-M) and Cox proportional hazards statistical modeling in JMP® & R®...
March 17, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28318643/cxcl10-alters-the-tumour-immune-microenvironment-and-disease-progression-in-a-syngeneic-murine-model-of-high-grade-serous-ovarian-cancer
#3
Katrina K Au, Nichole Peterson, Peter Truesdell, Gillian Reid-Schachter, Kasra Khalaj, Runhan Ren, Julie-Ann Francis, Charles H Graham, Andrew W Craig, Madhuri Koti
OBJECTIVE: We recently established that high STAT1 expression and associated T helper type I tumour immune microenvironment (TME) are prognostic and chemotherapy response predictive biomarkers in high-grade serous ovarian cancer (HGSC). STAT1 induced chemokine CXCL10 is key to the recruitment of lymphocytes in the TME and is significantly highly expressed in the tumours from patients with longer survival. In the current study we therefore aimed to elucidate the role CXCL10 in disease progression and tumour immune transcriptomic alterations using the ID8 syngeneic murine model of HGSC...
March 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28314589/fgfr2-mutations-are-associated-with-poor-outcomes-in-endometrioid-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#4
Yvette W Jeske, Shamshad Ali, Sara A Byron, Feng Gao, Robert S Mannel, Rahel G Ghebre, Paul A DiSilvestro, Shashikant B Lele, Michael L Pearl, Amy P Schmidt, Heather A Lankes, Nilsa C Ramirez, Golnar Rasty, Matthew Powell, Paul J Goodfellow, Pamela M Pollock
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS: Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up...
March 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28314588/risk-of-breast-cancer-after-a-diagnosis-of-ovarian-cancer-in-brca-mutation-carriers-is-preventive-mastectomy-warranted
#5
Jacob McGee, Vasily Giannakeas, Beth Karlan, Jan Lubinski, Jacek Gronwald, Barry Rosen, John McLaughlin, Harvey Risch, Ping Sun, William D Foulkes, Susan L Neuhausen, Joanne Kotsopoulos, Steven A Narod
OBJECTIVE: Preventive breast surgery and MRI screening are offered to unaffected BRCA mutation carriers. The clinical benefit of these two modalities has not been evaluated among mutation carriers with a history of ovarian cancer. Thus, we sought to determine whether or not BRCA mutation carriers with ovarian cancer would benefit from preventive mastectomy or from MRI screening. METHODS: First, the annual mortality rate for ovarian cancer patients was estimated for a cohort of 178 BRCA mutation carriers from Ontario, Canada...
March 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28292524/prevalence-of-lymph-node-metastasis-and-prognostic-significance-of-lymphadenectomy-in-apparent-early-stage-malignant-ovarian-sex-cord-stromal-tumors
#6
Dimitrios Nasioudis, Tomi T Kanninen, Kevin Holcomb, Giovanni Sisti, Steven S Witkin
OBJECTIVE: The aim of this retrospective population-based study was to investigate the prevalence of lymph node metastasis in patients with apparent early stage malignant sex cord-stromal tumors (SCSTs) and the effect of regional lymph node sampling/lymphadenectomy (LND) on their survival. METHODS: A cohort of patients diagnosed with malignant SCSTs between 1988 and 2012 was drawn from the National Cancer Institute's Surveillance, Epidemiology, and End Results database...
March 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28291545/adding-bevacizumab-to-single-agent-chemotherapy-for-the-treatment-of-platinum-resistant-recurrent-ovarian-cancer-a-cost-effectiveness-analysis-of-the-aurelia-trial
#7
Weiya Z Wysham, Elisabeth M Schaffer, Theresa Coles, Dario R Roque, Stephanie B Wheeler, Kenneth H Kim
OBJECTIVE: AURELIA, a randomized phase III trial of adding bevacizumab (B) to single agent chemotherapy (CT) for the treatment of platinum-resistant recurrent ovarian cancer, demonstrated improved progression free survival (PFS) in the B+CT arm compared to CT alone. We aimed to evaluate the cost effectiveness of adding B to CT in the treatment of platinum-resistant recurrent ovarian cancer. METHODS: A decision tree model was constructed to evaluate the cost effectiveness of adding bevacizumab (B) to single agent chemotherapy (CT) based on the arms of the AURELIA trial...
March 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285846/a-comparative-analysis-of-prediction-models-for-complete-gross-resection-in-secondary-cytoreductive-surgery-for-ovarian-cancer
#8
Renee A Cowan, Ane Gerda Zahl Eriksson, Sara M Jaber, Qin Zhou, Alexia Iasonos, Oliver Zivanovic, Mario M Leitao, Nadeem R Abu-Rustum, Dennis S Chi, Ginger J Gardner
OBJECTIVE: We sought to examine compliance and outcomes using Memorial Sloan Kettering "(MSK) criteria" to predict complete gross resection (CGR) and compare them with the validated Tian and AGO models. METHODS: Patients who underwent SCS for recurrent platinum-sensitive ovarian cancer from 5/2001-6/2014 were identified. The AGO and Tian models were applied to the study population; appropriate statistical tests were used to determine ability to predict CGR. RESULTS: 214 SCS cases were identified...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285845/a-stratified-randomized-double-blind-phase-ii-trial-of-celecoxib-for-treating-patients-with-cervical-intraepithelial-neoplasia-the-potential-predictive-value-of-vegf-serum-levels-an-nrg-oncology-gynecologic-oncology-group-study
#9
Janet S Rader, Michael W Sill, Jan H Beumer, Heather A Lankes, Doris Mangiaracina Benbrook, Francisco Garcia, Connie Trimble, J Tate Thigpen, Richard Lieberman, Rosemary E Zuna, Charles A Leath, Nick M Spirtos, John Byron, Premal H Thaker, Shashikant Lele, David Alberts
PURPOSE: To examine the effect of celecoxib on cervical intraepithelial neoplasia 3 (CIN 3). This is a NRG Oncology/Gynecologic Oncology Group study with translational biomarkers. PATIENTS AND METHODS: Patients with CIN 3 were randomized to celecoxib 400mg once daily (67 patients) or placebo (63 patients) for 14-18weeks. The primary outcome measure was histologic regression. A test of equal probabilities of success between two therapies was conducted, using Fisher's Exact Test at alpha=10% and 90% power when the treatment arm boosted the probability of success by 30%...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28284518/primary-lymphoma-of-the-female-genital-tract-an-analysis-of-697-cases
#10
Dimitrios Nasioudis, Polydoros N Kampaktsis, Melissa Frey, Steven S Witkin, Kevin Holcomb
OBJECTIVE: Primary lymphoma of the female genital tract (PLFGT) is a rare entity. The aim of this population-based study was to elucidate the clinico-pathological, demographic characteristics and survival of women with PLFGT. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results database was accessed and cases of PLFGT diagnosed between 1988 and 2012 were identified. Five-year overall (OS) and cancer-specific (CSS) survival rates were calculated with the Kaplan-Meier method...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28283195/effects-of-survivorship-care-plans-on-patient-reported-outcomes-in-ovarian-cancer-during-2-year-follow-up-the-rogy-care-trial
#11
Belle H de Rooij, Nicole P M Ezendam, Kim A H Nicolaije, M Caroline Vos, Johanna M A Pijnenborg, Dorry Boll, Erik A Boss, Ralph H M Hermans, Karin C M Engelhart, Joke E Haartsen, Brenda M Pijlman, Ingrid E A M van Loon-Baelemans, Helena J M M Mertens, Willem E Nolting, Johannes J van Beek, Jan A Roukema, Roy F P M Kruitwagen, Lonneke V van de Poll-Franse
OBJECTIVE: The aim of this study was to assess the long-term impact of an automatically generated Survivorship Care Plan (SCP) on patient reported outcomes in ovarian cancer in routine clinical practice. Outcome measures included satisfaction with information provision and care, illness perceptions and health care utilization. METHODS: In this pragmatic cluster randomized trial, twelve hospitals in the South of the Netherlands were randomized to 'SCP care' or 'usual care'...
March 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28279480/illness-perceptions-and-changes-in-lifestyle-following-a-gynecological-cancer-diagnosis-a-longitudinal-analysis
#12
Marlou E C L van Broekhoven, Belle H de Rooij, Johanna M A Pijnenborg, M Caroline Vos, Dorry Boll, Roy F P M Kruitwagen, Lonneke V van de Poll-Franse, Nicole P M Ezendam
OBJECTIVE: This study explores patterns of lifestyle change and whether more threatening illness perceptions are associated with lifestyle changes post-treatment for smoking, alcohol consumption and Body Mass Index (BMI) among gynecological cancer patients. METHODS: In total, 395 cancer patients (N=221 endometrial; N=174 ovarian) were included in this secondary analysis of longitudinal data. Lifestyle outcomes were assessed through self-reported questionnaires after initial treatment and 6, 12, and 18months of follow-up...
March 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28274569/predictive-value-of-circulating-tumor-cells-ctcs-captured-by-microfluidic-device-in-patients-with-epithelial-ovarian-cancer
#13
Maria Lee, Eun Jae Kim, Youngnam Cho, Sunshin Kim, Hyun Hoon Chung, Noh Hyun Park, Yong-Sang Song
OBJECTIVE: To test an electrically conductive chip, incorporating a nanoroughened microfluidic platform for the capture of circulating tumor cells (CTCs), and assess its clinical merit in instances of epithelial ovarian cancer (EOC). METHODS: A total of 54 patients with EOC recruited between August 2014 and May 2015 were enrolled in this prospective study. CTCs in peripheral blood were detected in advance of primary tumor resection and before initiating adjuvant chemotherapy for recurrent disease...
March 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28274568/differences-in-the-outcomes-and-complications-between-elderly-and-younger-uterine-cervical-cancer-patients-treated-by-definitive-radiotherapy-a-propensity-score-matched-study
#14
Yu-Ming Wang, Chong-Jong Wang, Fu-Min Fang, Hui-Chun Chen, Hsuan-Chih Hsu, Yu-Jie Huang, Chang-Yu Wang, Eng-Yen Huang
PURPOSE: To evaluate the differences in the treatment outcomes and complications between elderly patients and younger patients with uterine cervical cancer (CxCa). METHODS AND MATERIALS: From April 1993 to December 2007, 138 CxCa patients aged ≥75years (Elderly group) and 334 CxCa patients aged <60years (Young group) who underwent definitive radiotherapy/chemoradiotherapy at our institution were reviewed. Two propensity score-matched cohorts of patients were selected from both age groups to evaluate the differences in the outcomes and complications...
March 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28259424/long-term-incidence-of-female-specific-cancer-after-bariatric-surgery-or-usual-care-in-the-swedish-obese-subjects-study
#15
Åsa Anveden, Magdalena Taube, Markku Peltonen, Peter Jacobson, Johanna C Andersson-Assarsson, Kajsa Sjöholm, Per-Arne Svensson, Lena M S Carlsson
OBJECTIVE: To examine the long-term effects of bariatric surgery on female-specific cancer in women with obesity. METHODS: The prospective, matched Swedish Obese Subjects (SOS) study was designed to examine outcomes after bariatric surgery. This study includes 1420 women from the SOS cohort that underwent bariatric surgery and 1447 contemporaneously matched controls who received conventional obesity treatment. Age was 37-60years and BMI was ≥38kg/m(2). Information on cancer events was obtained from the Swedish National Cancer Registry...
March 1, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28258763/the-value-of-value-in-gynecologic-oncology-practice-in-the-united-states-society-of-gynecologic-oncology-evidence-based-review-and-recommendations
#16
David E Cohn, Emily Ko, Larissa A Meyer, Jason D Wright, Sarah M Temkin, Jonathan Foote, Nathaniel L Jones, Laura J Havrilesky
No abstract text is available yet for this article.
March 1, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28256320/the-times-they-are-a-changin-transformation-of-accreditation-and-certification-in-gynecologic-oncology
#17
Ronald D Alvarez, Wesley C Fowler
No abstract text is available yet for this article.
February 27, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28256319/corrigendum-to-the-sooner-the-better-genetic-testing-following-ovarian-cancer-diagnosis-gynecol-oncol-137-2015-423-429
#18
E Fox, J McCuaig, R Demsky, C Shuman, D Chitayat, M Maganti, J Murphy, B Rosen, S Ferguson, S Randall Armel
No abstract text is available yet for this article.
February 27, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28238563/the-development-and-use-of-vascular-targeted-therapy-in-ovarian-cancer
#19
REVIEW
Dana M Chase, David J Chaplin, Bradley J Monk
Combination vascular-targeted therapies (VTTs) represent a promising approach for patients with platinum-resistant recurrent ovarian cancer (OC). VTTs include two mechanistically distinct classes of agents: anti-angiogenic agents (AAs) and vascular-disrupting agents (VDAs). AAs suppress growth of new tumor vasculature through inhibition of vascular endothelial growth factor (VEGF) and other pro-angiogenic molecules. Bevacizumab, a monoclonal antibody that binds to VEGF, has improved progression-free survival (PFS) when given with chemotherapy in patients with advanced OC...
February 24, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28237618/updates-of-the-role-of-oxidative-stress-in-the-pathogenesis-of-ovarian-cancer
#20
REVIEW
Ghassan M Saed, Michael P Diamond, Nicole M Fletcher
Clinical and epidemiological investigations have provided evidence supporting the role of reactive oxygen species (ROS) and reactive nitrogen species (RNS), collectively known as oxidative stress, in the etiology of cancer. Exogenous factors such as chronic inflammation, infection and hypoxia are major sources of cellular oxidative stress. Specifically, oxidative stress plays an important role in the pathogenesis, neoangiogenesis, and dissemination of local or distant ovarian cancer, as it is known to induce phenotypic modifications of tumor cells by cross talk between tumor cells and the surrounding stroma...
February 23, 2017: Gynecologic Oncology
journal
journal
23122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"